Desktop Site
|
17 May 24 | 09:31
|
Open
Equity
SME
Eq Drv
Currency
Commodity
Corporates
Get Quote
*
Notices
|
S&P
BSE SENSEX
73,569.77
-93.95
-0.13 %
Corporate Announcement
Security Code
506820
Company
AstraZeneca Pharma India Ltd
Exchange Received Time
19/04/2024 14:12:45
Exchange Disseminated Time
19/04/2024 14:12:45
Time Taken
00:00:00
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A |
4/19/2024 2:12:45 PM
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
Sr. No.
Particulars
Details
1
Name of Company
ASTRAZENECA PHARMA INDIA LTD.
2
CIN NO.
L24231KA1979PLC003563
3
Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr)
0.00
4
Highest Credit Rating during the previous FY
000
4a
Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)
Not Applicable
5
Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the framework
BSE
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No
Name of the Company Secretary: Manasa R
Designation: Company Secretary
EmailId: manasa.r1@astrazeneca.com
Name of the Chief Financial Officer: Bhavana Agrawal
Designation: Chief Financial Officer and Director
EmailId: bhavana.agrawal@astrazeneca.com
Date: 19/04/2024
Note:
In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Attachment
<< Back
Recently Viewed